2011
DOI: 10.4172/plastic-surgery.1000688
|View full text |Cite
|
Sign up to set email alerts
|

Treatment of keratoacanthoma: Is intralesional methotrexate an option?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
17
0

Year Published

2013
2013
2021
2021

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 13 publications
(17 citation statements)
references
References 13 publications
(15 reference statements)
0
17
0
Order By: Relevance
“…No abnormalities in laboratory tests have been identified, and after an average of 2.8 years of follow-up, lesions have not recurred. 2 Based on this experience, neoadjuvant methotrexate use was reported in a 51-year-old man with squamous cell carcinoma of the lower lip. He received three injections of the drug, with doses ranging from 17.5 to 25 mg.…”
Section: Discussionmentioning
confidence: 98%
See 1 more Smart Citation
“…No abnormalities in laboratory tests have been identified, and after an average of 2.8 years of follow-up, lesions have not recurred. 2 Based on this experience, neoadjuvant methotrexate use was reported in a 51-year-old man with squamous cell carcinoma of the lower lip. He received three injections of the drug, with doses ranging from 17.5 to 25 mg.…”
Section: Discussionmentioning
confidence: 98%
“…Photodynamic therapy (PDT) is an effective, cosmetically favorable therapy for premalignant and malignant dermatologic conditions such as actinic keratoses, Bowen's disease, and superficial basal cell carcinoma (BCC), but there have been recent case reports of rapidly progressing cutaneous malignancy arising in patients who have undergone PDT. [1][2][3] We would like to share our similar experience with two patients who had rapid progress from Bowen's disease to locally invasive squamous cell carcinoma (SCC) after PDT.…”
Section: Discussionmentioning
confidence: 99%
“…Until now, two randomized controlled studies [28,30] and five clinical observational studies [6,29,[31][32][33] have demonstrated efficacy of topical MTX-treatments for patients with psoriasis. In addition, several studies demonstrate partial or complete remission of keratoacanthomas after intralesional MTX injections [34][35][36][37]. Thus, available literature suggests that topical MTX is a potential efficient treatment of dermatological diseases and there is reason to believe that topical and systemic MTX has a similar onset of action.…”
Section: Discussionmentioning
confidence: 99%
“…15,17 Current theory suggests reclassification of keratoacanthomas as either premalignant lesions or, furthermore, as a subtype of squamous cell carcinoma. [16][17][18][19] Conservative treatment modalities such as 5-fluorouracil, imiquimod, and intralesional methotrexate are considered second-line therapies, and early surgical excision is recommended. 15,17 …”
Section: Pyogenic Granulomasmentioning
confidence: 99%